Iovance Biotherapeutics
About:
Iovance Biotherapeutics is developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Website: http://www.iovance.com
Twitter/X: iovancebio
Top Investors: OrbiMed, Frazier Healthcare Partners, Quogue Capital, Broadfin Capital
Description:
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). The company is preparing for potential regulatory approval and marketing of the first autologous T-cell treatment for solid tumor cancer in the United States. Its goal is to be the leader in tumor-infiltrating lymphocyte, or TIL, therapy innovation, development, and delivery for patients with solid tumor malignancies.
$1.58B
$50M to $100M
New York, New York, United States
2007-01-01
info(AT)iovance.com
Manish Singh
501-1000
2024-02-20
Public
© 2025 bioDAO.ai